Eledon Pharmaceuticals (ELDN) Return on Equity (2014 - 2026)

Eledon Pharmaceuticals (ELDN) has 13 years of Return on Equity data on file, last reported at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity fell 1.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (down 1.0% YoY), and the FY2025 full-year result was 0.01%, up 5.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.01%, up from 0.01% in the prior quarter.
• Across five years, Return on Equity topped out at 0.04% in Q4 2023 and bottomed at 0.02% in Q3 2023.
• The 5-year median for Return on Equity is 0.0% (2025), against an average of 0.0%.
• The widest annual swing landed in 2023, when Return on Equity grew 5 bps; it then slipped 4 bps in 2024.
• A 5-year view of Return on Equity shows it stood at 0.01% in 2022, then surged by 456 bps to 0.04% in 2023, then tumbled by 105 bps to 0.0% in 2024, then slumped by 485 bps to 0.01% in 2025, then climbed by 3 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.

Peer Comparison